NeuroPASS Device Platform
Aggressive Brain Tumors, Alzheimer's Disease, Parkinson's Disease
Pre-clinicalActive
Key Facts
Indication
Aggressive Brain Tumors, Alzheimer's Disease, Parkinson's Disease
Phase
Pre-clinical
Status
Active
Company
About CraniUS Therapeutics
CraniUS Therapeutics is pioneering a novel, implantable drug delivery platform to treat central nervous system disorders. Its flagship NeuroPASS™ device is a fully skull-implantable system that delivers microdoses of therapeutics directly to the brain, bypassing the blood-brain barrier. The technology, currently in pre-clinical development, targets aggressive brain tumors, Alzheimer's, and Parkinson's disease with the goal of improving efficacy and reducing systemic toxicity. Early large animal studies have demonstrated promising results in achieving convective distribution within brain tissue.
View full company profile